Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 6, 2005, Pages 1071-1086

  Nofer, Jerzy Roch ^a   Walter, Michael ^a   Assmann, Gerd ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Aging; Apolipoprotein A I; Atherosclerosis; High density lipoproteins; Inflammation; Lysosphingolipids; Oxidation

Indexed keywords

ABC TRANSPORTER A1; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; ATORVASTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LYSOPHOSPHOLIPID; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLCHOLINE; PRAVASTATIN; PROTEIN KINASE B; SCAVENGER RECEPTOR; SPHINGOSINE KINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; CELL TRANSPORT; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DNA REPLICATION; ELECTROPHORETIC MOBILITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC RISK; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; INHIBITION KINETICS; LEUKOCYTE ADHERENCE; LIPID METABOLISM; LIPID TRANSPORT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MORTALITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATION; PREDICTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RISK REDUCTION; SENESCENCE; STRUCTURE ANALYSIS; TELOMERE; UPREGULATION; VASODILATATION;

AGING; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT, ACTIVE; CHOLESTEROL; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL;

EID: 28644433849     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.3.6.1071     Document Type: Review

References (148)

1. Assmann G, Nofer JR. The protective role of HDL. In: Lectures in Clinical Atherosclerosis and Dyslipidemia, Part 3. Carlson LA (Ed.). Current Medical Group, Science Press, London, UK (2005).
2. Hersberger M, von Eckardstein A. Low high density lipoprotein cholesterol - physiological background, clinical importance and drug treatment. Drugs 63, 1907-1945 (2003).
3. Assmann G, Nofer J-R. Atheroprotective effects of high density lipoproteins. Ann. Rev. Med. 54, 321-341 (2003).
4. Barrans A, Jaspard B, Barbaras R, Chap H, Perret B, Collet X. Preβ HDL: structure and metabolism. Biochim. Biophys. Acta 1300, 73-85 (1996).
5. Rye KA, Barter PJ. Formation and metabolism of preβ-migrating, lipid-poor apolipoprotein A-I. Arterioscler. Thromb. Vasc. Biol. 24, 421-428 (2004).
6. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 1221-1232 (2005).
7. Bolibar I, von Eckardstein A, Assmann G, Thompson S; ECAT Angina Pectoris Study Group. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb. Haemost. 84, 955-960 (2000).
8. Moestrup SK, Nielsen LB. The role of the kidney in lipid metabolism. Curr. Opin. Lipidol. 16, 301-306 (2005).
9. Davidson WS, Sparks DL, Lund-Katz S, Phillips MC. The molecular basis for the difference in charge between pre-β- and α-migrating high density lipoproteins. J. Biol. Chem. 269, 8959-8965 (1994).
10. Dawson G, Kruski AW, Scanu AM. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J. Lipid. Res. 17, 125-131 (1976).
11. Hara A, Taketomi T. Occurrence of sulfatide as a major glycosphingolipid in WHHL rabbit serum lipoproteins. J. Biochem. 102, 83-92 (1987).
12. 2. Blood 86, 4166-4174 (1995).
13. 2+ in cultured fibroblasts. Biochem. J. 279, 29-33 (1991).
14. Murata N, Sato K, Kon J et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352, 809-815 (2000).
15. 3. J. Clin. Invest. 113, 569-581 (2004).
16. Nofer JR, Fobker M, Hobbel G et al. Activation of phosphatidylinositol-specific phospholipase C by HDL-associated lysosphingolipid. Involvement in mitogenesis but not in cholesterol efflux. Biochemistry 39, 15199-15207 (2000).
17. Zhang B, Tomura H, Kuwabara A et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 178, 199-205 (2005).
18. Rader D. Regulation of reverse cholesterol transport and clinical implications. Am. J. Cardiol. 92, J42-J49 (2003).
19. Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell. Mol. Life Sci. 61, 682-699 (2004).
20. Pohl A, Devaux PF, Herrmann A. Function of prokaryotic and eukaryotic ABC proteins in lipid transport. Biochim. Biophys. Acta 1733, 29-52 (2005).
21. Assmann G, von Eckardstein A, Brewer HB Jr. Familial high density lipoprotein deficiency: tangier disease. In: The Metabolic and Molecular Bases of Inherited Diseases. Scriver CR, Beaudet AL, Valle WS, Sly D (Eds). MacGraw-Hill, New York, USA, 2053-2072, (1995).
22. Howell KE, Palade GE. Heterogeneity of lipoprotein particles in hepatic golgi fractions. J. Cell Biol. 92, 833-845 (1982).
23. Banerjee D, Redman CM. Biosynthesis of high density lipoprotein by chicken liver: conjugation of nascent lipids with apoprotein A1. J. Cell Biol. 99, 1917-1926 (1984).
24. Banerjee D, Redman CM. Biosynthesis of high density lipoprotein by chicken liver: nature of nascent intracellular high density lipoprotein. J. Cell Biol. 96, 651-660 (1983).
25. Castle CK, Pape ME, Marotti KR, Melchior GW. Secretion of pre-β-migrating apo-A-I by cynomolgus monkey hepatocytes in culture. J. Lipid Res. 32, 439-447 (1991).
26. Forte TM, Goth-Goldstein R, Nordhausen RW, McCall MR. Apolipoprotein A-I-cell membrane interaction: extracellular assembly of heterogeneous nascent HDL particles. J. Lipid Res. 34, 317-324 (1993).
27. Sahoo D, Trischuk TC, Chan T et al. ABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytes. J. Lipid Res. 45, 1122-1131 (2004).
28. Chisholm JW, Burleson ER, Shelness GS, Parks JS. ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL. J. Lipid Res. 43, 36-44 (2002).
29. Kiss RS, McManus DC, Franklin V et al. The lipidation by hepatocytes of human apolipoprotein A-I occurs by both ABCA1-dependent and -independent pathways. J. Biol. Chem. 278, 10119-10127 (2003).
30. Tsujita M, Wu CA, Abe-Dohmae S, Usui S, Okazaki M, Yokoyama S. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J. Lipid Res. 46, 154-162 (2005).
31. Liu L, Bortnick AE, Nickel M et al. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J. Biol. Chem. 278, 42976-42984 (2003).
32. Denis M, Haidar B, Marcil M, Bouvier M, Krimbou L, Genest J. Characterization of oligomeric human ATP binding cassette transporter A1. Potential implications for determining the structure of nascent high density lipoprotein particles. J. Biol. Chem. 279, 41529-41536 (2004).
33. Lee JY, Timmins JM, Mulya A et al. Plasma HDL in human apoA-I transgenic-Abca1 knockout mice undergo normal intravascular remodeling but are hypercatabolized by the kidney. J. Lipid Res. (2005).
34. Marcil M, Brooks-Wilson A, Clee SM et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354, 1341-1346 (1999).
35. Hovingh GK, Van Wijland MJ, Brownlie A et al. The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. J. Lipid Res. 44, 1251-1255 (2003).
36. Mott S, Yu L, Marcil M, Boucher B, Rondeau C, Genest J Jr. Decreased cellular cholesterol efflux is a common cause of familial hypoαlipoproteinemia: role of the ABCA1 gene mutations. Atherosclerosis 152, 457-468 (2000).
37. Alenezi MY, Marcil M, Blank D, Sherman M, Genest J Jr. Is the decreased high-density lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect? J. Clin. Endocrinol. Metab. 89, 761-764 (2004).
38. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J. Clin. Invest. 114, 1343-1353 (2004).
39. Vaisman BL, Lambert G, Amar M, Joyce C et al. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. 108, 303-309 (2001).
40. Singaraja RR, Bocher V, James ER et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J. Biol. Chem. 276, 33969-33979 (2001).
41. Basso F, Freeman L, Knapper CL et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J. Lipid Res. 44, 296-302 (2003).
42. Wellington CL, Brunham LR, Zhou S et al. Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J. Lipid Res. 44, 1470-1480 (2003).
43. Timmins JM, Lee JY, Boudygina E et al. Targeted inactivation of hepatic ABCA1 causes profound hypoalhalipoproteinemia and kidney hypercatabolism of apo A-I. J. Clin. Invest. 115, 1333-1342 (2005).
44. Hayden MR. Tissue specific of ABCA1 to HDL biogenesis. VI Annual Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, WA, USA, April 28-30, (2005).
45. Aiello RJ, Brees D, Bourassa PA et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22, 630-637 (2002).
46. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 108, 1315-1320 (2001).
47. van Eck M, Bos IS, Kaminski WE et al. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl Acad. Sci. USA 99, 6298-6303 (2002).
48. McNeish J, Aiello RJ, Guyot D et al. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. USA 97, 4245-4250 (2000).
49. Wang N, Lan D, Gerbod-Giannone M et al. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J. Biol. Chem. 278, 42906-42912 (2003).
50. Abe-Dohmae S, Ikeda Y, Matsuo M et al. Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein. J. Biol. Chem. 279, 604-611 (2004).
51. Linsel-Nitschke P, Jehle AW, Shan J et al. Potential role of ABCA7 in cellular lipid efflux to apoA-I. J. Lipid Res. 46, 86-92 (2005).
52. Kim WS, Fitzgerald ML, Kang K et al. AbcA7 null mice retain normal macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in adipose mass and serum cholesterol levels. J. Biol. Chem. 280, 3989-3995 (2005).
53. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl Acad. Sci. USA 101, 9774-9779 (2004).
54. Kennedy MA, Barrera GC, Nakamura K et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1, 121-131 (2005).
55. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 109 (21 Suppl. 1), II2-II10 (2004).
56. Libby P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002).
57. Endemann DH, Schiffrin EL. Endothelial dysfunction. J. Am. Soc. Nephrol. 15, 1983-1892 (2004).
58. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 83, 1069-1112 (2003).
59. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ. Res. 95, 858-866 (2004).
60. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 161, 1-16 (2002).
61. Sevanian A, Bittolo-Bon G, Cazzolato G et al. LDL is a lipid hydroperoxide-enriched circulating lipoprotein. J. Lipid Res. 38, 419-428 (1997).
62. Navab M, Berliner JA, Subbanagounder G et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21, 481-488 (2001).
63. Navab M, Hama SY, Cooke CJ et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41, 1481-1494 (2000).
64. Navab M, Hama SY, Anantharamaiah GM et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J. Lipid Res. 41, 1495-1508 (2000).
65. Garber DW, Datta G, Chaddha M et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42, 545-552 (2001).
66. Navab M, Anantharamaiah GM, Hama S et al. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105, 290-292 (2002).
67. Navab M, Anantharamaiah GM, Reddy ST et al. Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 109, 3215-3120 (2004).
68. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for a direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins A-I and A-II. J. Biol. Chem. 273, 6088-6095 (1998).
69. Shih DM, Gu L, Yia YR et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394, 284-287 (1998).
70. Shih DM, Xia YR, Wang XP et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275, 17527-17535 (2000).
71. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem. Biophys. Res. Commun. 290, 921-927 (2002).
72. Navab M, Anantharamaiah GM, Hama S et al. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 25, 1426-1432 (2005).
73. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem. Biophys. Res. Commun. 318, 680-683 (2004).
74. Barter PJ, Baker PW, Rye KA. Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr. Opin. Lipidol. 13, 285-288 (2002).
75. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J. Lipid. Res. 40, 345-353 (1999).
76. Baker PW, Rye KA, Gamble JR, Vadas MA, Barter PJ. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J. Lipid Res. 41, 1261-1267 (2000).
77. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against Atherosclerosis by HDL. J. Biol. Chem. 274, 33143-33147 (1999).
78. Hyka N, Dayer JM, Modoux C et al. Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T-lymphocytes. Blood. 97, 2381-2389 (2001).
79. Van Lenten BJ, Wagner AC, Navab M et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human Type II pneumocytes. Circulation. 110, 3252-3258 (2004).
80. Cockerill GW, McDonald MC, Mota-Filipe H, Cuzzocrea S, Miller NE, Thiemermann C. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J. 15, 1941-1952 (2001).
81. McDonald MC, Dhadly P, Cockerill GW et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 20, 551-557 (2003).
82. Calabresi L, Rossoni G, Gomaraschi M, Sisto F, Berti F, Franceschini G. High-density lipoproteins protect isolated rat hearts from ischaemia-reperfusion injury by reducing cardiac tumor necrosis factor-α content and enhancing prostaglandin release. Circ. Res. 92, 330-337 (2003).
83. Rossoni G, Gomaraschi M, Berti F, Sirtori CR, Franceschini G, Calabresi L. Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischaemia/reperfusion injury. J. Pharmacol. Exp. Ther. 308, 79-84 (2004).
84. Thiemermann C, Patel NS, Kvale EO et al. High density lipoprotein (HDL) reduces renal ischaemia/reperfusion injury. J. Am. Soc. Nephrol, 14, 1833-1843 (2003).
85. Zabalawi M, Bhat S, Loughlin T et al. Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol. Am. J. Pathol. 163, 1201-1213 (2003).
86. Sampietro T, Bigazzi F, Dal Pino B et al. Increased plasma C-reactive protein in familial hypo-α-lipoproteinemia: a proinflammatory condition? Circulation 105, 11-14 (2002).
87. Nofer JR, Geigenmuller S, Gopfert C et al. High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem. Biophys. Res. Commun. 310, 98-103 (2003).
88. Bolick DT, Srinivasan S, Kim KW et al. Sphingosine-1-phosphate prevents tumor necrosis factor-{α}-mediated monocyte adhesion to aortic endothelium in mice. Arterioscler. Thromb. Vasc. Biol. 25, 976-981 (2005).
89. Spieker LE, Sudano I, Hurlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105, 1399-1402 (2002).
90. Bisoendial RJ, Hovingh GK, Levels JH et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107, 2944-2948 (2003).
91. Yuhanna IS, Zhu Y, Cox BE et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nature Med. 7, 853-857 (2001).
92. Mineo C, Yuhanna IS, Quon MJ et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAPKs. J. Biol. Chem. 278, 9142-9149 (2003).
93. Ramet ME, Ramet M, Lu Q et al. High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J. Am. Coll. Cardiol. 41, 2288-2297 (2003).
94. Nofer JR, Levkau B, Wolinska I et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J. Biol. Chem. 276, 34480-34485 (2001).
95. Kimura T, Sato K, Kuwabara A et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J. Biol. Chem. 276, 31780-32532 (2001).
96. Kimura T, Sato K, Malchinkhuu E et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. 23, 1283-1288 (2003).
97. Norata GD, Callegari E, Marchesi M et al. High-density lipoproteins induce transforming growth factor-β2 expression in endothelial cells. Circulation 111, 2805-2811 (2005).
98. Mallat Z, Tedgui A. The role of transforming growth factor β in Atherosclerosis: novel insights and future perspectives. Curr. Opin. Lipidol. 13, 523-529 (2002).
99. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG. High-density vs. low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch. Intern. Med. 163, 1549-1554 (2003).
100. Wilson PWF, Anderson KM, Harris T, Kannel WB, Castelli WP. Determinants of change in total cholesterol and HDLC with age: the Framingham study. J. Gerontol. 49, M252-M257 (1994).
101. Schaefer EJ, Moussa PB, Wilson PW, McGee D, Dallal G, Castelli WP. Plasma lipoproteins in healthy octogenarians: lack of reduced high density lipoprotein cholesterol levels: results from the Framingham Heart Study. Metabolism 38, 293-296 (1989).
102. Barter P. HDL: a recipe for longevity. Atherosclerosis 5(Suppl.), 25-31 (2004).
103. Abbott RD, Sharp DS, Burchfiel CM et al. Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program. Ann. Epidemiol. 7, 417-424 (1997).
104. Barzilai N, Gabriely I, Gabriely M, Iankowitz N, Sorkin JD. Offspring of centenarians have a favorable lipid profile. J. Am. Geriatr. Soc. 49, 76-79 (2001).
105. Barzilai N, Atzmon G, Schechter C et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290, 2030-2040 (2003).
106. Ferrara A, Barrett-Connor E, Shan J. Total, LDL, and HDL cholesterol decrease with age in older men and women. The Rancho Bernardo Study 1984-1994. Circulation 96, 37-43 (1997).
107. Walter M, Forsyth NR, Wright WE, Shay JW, Roth MG. The establishment of telomerase-immortalized Tangier disease cell lines indicates the existence of an apolipoprotein A-I-inducible but ABCA1-independent cholesterol efflux pathway. J. Biol. Chem. 279, 20866-20873 (2004).
108. Wright WE, Shay JW. Historical claims and current interpretations of replicative aging. Nature Biotechnol. 20, 682-688 (2002).
109. Bodnar AG, Ouellette M, Frolkis M et al. Extension of lifespan by introduction of telomerase into normal human cells. Science 279, 349-352 (1998).
110. Zhang Z, Hirano K, Tsukamoto K et al. Defective cholesterol efflux in Werner syndrome fibroblasts and its phenotypic correction by Cdc42, a RhoGTPase. Exp. Gerontol. 40, 286-294 (2005).
111. Clee SM, Kastelein JJ, van Dam M et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J. Clin. Invest. 106, 1263-1270 (2000).
112. Efferth T. Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases. Ageing Res. Rev. 2, 11-24 (2003).
113. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 105, 1541-1544 (2002).
114. Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23, 842-846 (2003).
115. Cawthon RM, Smith KR, O'Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet 361, 393-395 (2003).
116. Wright WE, Shay JW. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nature Med. 6, 849-851 (2000).
117. Shay JW, Wright WE. Telomeres are double-strand DNA breaks hidden from DNA damage responses. Mol. Cell 14, 420-421 (2004).
118. Fernandez C, Lobo Mdel V, Gomez-Coronado D, Lasuncion MA. Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp. Cell. Res. 300, 109-120 (2004).
119. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
120. Waters DD, Guyton JR, Herrington DM et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 93, 154-158 (2004).
121. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
122. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature Rev. Drug Discov. 4, 193-205 (2005).
123. Duffy D, Rader DJ. Drugs in development: targeting high-density lipoprotein Metabolism and reverse cholesterol transport. Curr. Opin. Cardiol. 20, 301-306 (2005).
124. Nicholls SJ, Rye KA, Barter PJ. High-density lipoproteins as therapeutic targets. Curr. Opin. Lipidol. 16, 345-349 (2005).
125. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized Phase II dose-response study. Circulation 105, 2159-2165 (2002).
126. Clark RW, Sutfin TA, Ruggeri RB et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490-497 (2004).
127. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350, 1505-1515 (2004).
128. Brousseau ME, Diffenderfer MR, Millar JS et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25, 1057-1064 (2005).
129. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85, 1234-1241 (1990).
130. Milano on coronary Atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300 (2003).
131. Barter PJ, Nicholls S, Rye KA et al. Anti-inflammatory properties of HDL. Circ. Res. 95, 764-772. (2004).
132. Navab M, Anantharamaiah GM, Reddy ST et al. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 4, 1100-1104 (2003).
133. Navab M, Anantharamaiah GM, Reddy ST et al. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr. Opin. Lipidol. 15, 645-649 (2004).
134. Navab M, Anantharamaiah GM, Reddy ST et al. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 25, 1325-1331 (2005).
135. Brinkmann V, Lynch KR. FTY720: targeting G-protein coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr. Opin. Immunol. 14, 569-575 (2002).
136. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4, 1019-1025 (2004).
137. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278, 9869-9874 (2003).
138. Tunaru S, Kerc J, Schaub A et al. PUMA-G and HM74 are receptors fbr nicotinic acid and mediate its antilipolytic effect. Nature Med. 9, 352-355 (2003).
139. Pike NB, Wise A. Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug? Curr. Opin. Investig. Drugs 5, 271-275 (2004).
140. Saad MF, Greco S, Osei K et al. Ragaglitazar improves glycemic control and lipid profile in Type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27, 1324-1329 (2004).
141. Skrumsager BK, Nielsen KK, Muller M et al. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR α and γ agonist in healthy subjects and patients with Type 2 diabetes. J. Clin. Pharmacol. 43, 1244-1256 (2003).
142. Chakrabarti R, Vikramadithyan RK, Misra P et al. Ragaglitazar: a novel PPAR α PPAR γ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br. J. Pharmacol. 140, 527-537 (2003).
143. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 17, 985-93 (2003).
144. Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45, 2161-2173 (2004).
145. Joseph SB, Tontonoz P. LXRs: new therapeutic targets in Atherosclerosis? Curr. Opin. Pharmacol. 3, 192-197 (2003).
146. Jaye M. LXR agonists for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 4, 1053-1058 (2003).
147. Millatt LJ, Bocher V, Fruchart JC, Staels B. Liver X receptors and the control of cholesterol homeostasis: potential therapeutic targets for the treatment of Atherosclerosis. Biochim. Biophys. Acta. 1631, 107-118 (2003).
148. Collins JL. Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Discov. Devel. 7, 692-702 (2004).